The investigator's laboratory is studying a skin disease known as psoriasis. The purpose of
this protocol is to study the action and the effects of Etanercept, on psoriasis. This
medication has been studied extensively and has been found to be effective and safe in the
treatment of psoriasis. The eligible patient will have 10% of his/her body surface area
involved with psoriasis vulgaris. This trial is a phase III study to help understand the
action of the drug etanercept, trade name Enbrel, for the adult patient with moderate to
severe plaque psoriasis and who is a candidate for internal medications.
The eligible patient will receive the drug Etanercept (Enbrel), and will self inject with
Etanercept twice a week for the first 12 weeks. The patient will be taught to self inject
the medication at home and will be seen in the clinic weekly, for the first four weeks and
then once a month.
During the second 12 weeks of the study, patients will be placed in one of two groups by the
drug company participating. One group of patients will be randomized to either continue
receiving the medication and will self inject once a week. A second group will be randomized
to not receive the medication but will continue to be followed and examined at monthly
visits. The drug company will do the randomization or choice of group, and each patient has
a one in two chance of being placed in one group or the other.
At the clinic visits, the patient can expect that a physical exam and skin exam will be
done. At specific weeks, blood work will be drawn, clinical photography taken and a skin
biopsy done. Two types of skin biopsies will be done after local anesthesia has been
administered. One is a punch biopsy where a small piece of skin will be taken, the
approximate size of a pencil eraser. The second type of skin biopsy is a shave biopsy,
where a postage sized piece of skin will be taken.
- Gender: Male and Female
- Minimum Age: 18
- Maximum Age: 70
- Healthy Volunteers